Full metadata record
DC FieldValueLanguage
dc.creatorWalker, B.A. (Brian A.)-
dc.creatorMavrommatis, K. (Konstantinos)-
dc.creatorWardell, C.P. (Christopher P.)-
dc.creatorAshby, T.C. (T. Cody)-
dc.creatorBauer, M. (Michael)-
dc.creatorDavies, F. (Faith)-
dc.creatorRosenthal, A. (Adam)-
dc.creatorWang, H. (Hongwei)-
dc.creatorQu, P. (Pingping)-
dc.creatorHoering, A. (Antje)-
dc.creatorSamur, M. (Mehmet)-
dc.creatorTowfic, F. (Fadi)-
dc.creatorOrtiz, M. (María)-
dc.creatorFlynt, E. (Erin)-
dc.creatorYu, Z. (Zhinuan)-
dc.creatorYang, Z. (Zhihong)-
dc.creatorRozelle, D. (Dan)-
dc.creatorObenauer, J. (John)-
dc.creatorTrotter, M. (Matthew)-
dc.creatorAuclair, D. (Daniel)-
dc.creatorKeats, J.J. (Jonathan J.)-
dc.creatorBolli, N. (Niccolo)-
dc.creatorFulciniti, M. (Mariateresa)-
dc.creatorSzalat, R. (Raphael)-
dc.creatorMoreau, P. (Philippe)-
dc.creatorDurie, B. (B.)-
dc.creatorStewart, A.K. (A. Keith)-
dc.creatorGoldschmidt, H. (Hartmut)-
dc.creatorRaab, M.S. (Marc S.)-
dc.creatorEinsele, H. (Hermann)-
dc.creatorSonneveld, P. (Pieter)-
dc.creatorSan-Miguel, J.F. (Jesús F.)-
dc.creatorLonial, S. (Sagar)-
dc.creatorJackson, G.H. (Graham H.)-
dc.creatorAnderson, K.C. (K.C.)-
dc.creatorAvet-Loiseau, H. (Herve)-
dc.creatorMunshi, N.C. (Nikhil C.)-
dc.creatorThakurta, A. (Anjan)-
dc.creatorMorgan, G.J. (Gareth J.)-
dc.date.accessioned2021-09-20T08:13:12Z-
dc.date.available2021-09-20T08:13:12Z-
dc.date.issued2019-
dc.identifier.citationWalker, B.A. (Brian A.); Mavrommatis, K. (Konstantinos); Wardell, C.P. (Christopher P.); et al. "A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis". Leukemia. 33, 2019, 159 - 170es_ES
dc.identifier.issn0887-6924-
dc.identifier.otherPMID: 29967379-
dc.identifier.urihttps://hdl.handle.net/10171/62017-
dc.description.abstractPatients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.es_ES
dc.description.sponsorshipFunding for data processing and storage provided by Celgene Corporation.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Science and Business Media LLCes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectMaterias Investigacion::Ciencias de la Salud::Oncologíaes_ES
dc.titleA high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.es_ES
dc.identifier.doi10.1038/s41375-018-0196-8-
dadun.citation.endingPage170es_ES
dadun.citation.publicationNameLeukemiaes_ES
dadun.citation.startingPage159es_ES
dadun.citation.volume33es_ES

Files in This Item:
Thumbnail
File
s41375-018-0196-8.pdf
Description
Size
3.87 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.